Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
HUTCHMED (NASDAQ/AIM/HKEX:HCM) has announced an upcoming Research & Development update event scheduled for October 31, 2025. The presentation will feature Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer, who will discuss the company's R&D strategy and vision.
The event will highlight HUTCHMED's Antibody Targeted Therapy Conjugates platform, including updates on their lead candidate HMPL-A251 and late-stage pipeline developments. The presentation will be held in-person in Shanghai from 3:00-5:00 p.m. HKT in Chinese, with a concurrent webcast. An English webcast will follow at 8:00 p.m. HKT/8:00 a.m. EDT.
HUTCHMED (NASDAQ/AIM/HKEX:HCM) ha comunicato un prossimo aggiornamento su Ricerca e Sviluppo, previsto per 31 ottobre 2025. La sessione vedrà la partecipazione di Dr. Michael Shi, Vice Presidente Esecutivo, Responsabile R&S e Chief Medical Officer, che esporrà la strategia e la visione di R&D dell’azienda.
L’evento metterà in risalto la piattaforma Antibody Targeted Therapy Conjugates di HUTCHMED, includendo aggiornamenti sul candidato principale HMPL-A251 e sugli sviluppi del portafoglio in fase avanzata. La presentazione si svolgerà in presenza a Shanghai dalle 15:00 alle 17:00 (HKT) in cinese, con webcast contemporaneo. Un webcast in inglese seguirà alle 20:00 HKT/08:00 EDT.
HUTCHMED (NASDAQ/AIM/HKEX:HCM) ha anunciado una próxima actualización de I+D, programada para el 31 de octubre de 2025. La presentación contará con Dr. Michael Shi, Vicepresidente Ejecutivo, Responsable de I+D y Director Médico, quien abordará la estrategia y la visión de I+D de la empresa.
El evento destacará la plataforma Antibody Targeted Therapy Conjugates de HUTCHMED, con actualizaciones sobre su candidato principal HMPL-A251 y avances en su pipeline en etapas tardías. La sesión se celebrará en Shanghai, de forma presencial de 15:00 a 17:00, Hora estándar de Hong Kong (HKT) en chino, con webcast simultáneo. Un webcast en inglés seguirá a las 20:00 HKT/08:00 EDT.
HUTCHMED (NASDAQ/AIM/HKEX:HCM)가 2025년 10월 31일 예정된 연구개발 업데이트 이벤트를 발표했습니다. 발표에는 Dr. Michael Shi 상무 부사장 겸 연구개발 책임자 겸 최고의료책임자(CMO)가 참석하여 회사의 R&D 전략과 비전을 논의할 예정입니다.
본 행사는 Antibody Targeted Therapy Conjugates 플랫폼과 함께 주요 후보물질 HMPL-A251에 대한 업데이트 및 후기 단계 파이프라인의 개발 상황을 중점적으로 다룰 것입니다. 행사는 중국 상하이에서 현장 진행되며 현지 시간 15:00-17:00(HKT)로 진행되며 중국어 발표이며 동시 웹캐스트가 제공됩니다. 영어 웹캐스트는 이후 20:00 HKT/08:00 EDT에 진행됩니다.
HUTCHMED (NASDAQ/AIM/HKEX:HCM) a annoncé une prochaine mise à jour sur la Recherche et le Développement, prévue pour le 31 octobre 2025. La présentation mettra en lumière Dr. Michael Shi, Vice-président exécutif, Responsable R&D et Directeur médical, qui discutera de la stratégie et de la vision R&D de l’entreprise.
L’événement mettra en avant la plateforme Antibody Targeted Therapy Conjugates de HUTCHMED, avec des mises à jour sur le candidat principal HMPL-A251 et les évolutions du pipeline en stade avancé. La présentation se tiendra en personne à Shanghai de 15h00 à 17h00 (HKT) en chinois, avec une webdiffusion simultanée. Une webdiffusion en anglais suivra à 20h00 HKT/08h00 EDT.
HUTCHMED (NASDAQ/AIM/HKEX:HCM) hat ein kommendes Update zu Forschung & Entwicklung angekündigt, das für den 31. Oktober 2025 vorgesehen ist. Die Präsentation wird Dr. Michael Shi, Executive Vice President, Head of R&D und Chief Medical Officer, vorstellen, der die R&D-Strategie und Vision des Unternehmens erläutern wird.
Die Veranstaltung wird die Antibody Targeted Therapy Conjugates-Plattform von HUTCHMED hervorheben, einschließlich Updates zu ihrem führenden Kandidaten HMPL-A251 und Entwicklungen im späten Pipeline-Bereich. Die Präsentation findet persönlich in Shanghai von 15:00 bis 17:00 Uhr (HKT) auf Chinesisch statt, mit einem gleichzeitigen Webcast. Ein englischer Webcast folgt um 20:00 HKT/08:00 EDT.
HUTCHMED (NASDAQ/AIM/HKEX:HCM) قد أعلنت عن حدث تحديث في البحث والتطوير قريباً، المقرر في 31 أكتوبر 2025. ستتضمن العرض الدكتور مايكِل شي، نائب رئيس تنفيذي، رئيس قسم البحث والتطوير ومدير الطبّي، الذي سيناقش استراتيجية ورؤية الشركة في البحث والتطوير.
سيبرز الحدث منصة Antibody Targeted Therapy Conjugates لدى HUTCHMED، بما في ذلك تحديثات عن المرشح الرائد HMPL-A251 وتطورات خط الإنتاج المتأخر. سيُعقد العرض حضورياً في شنغهاي من 15:00 إلى 17:00 بالتوقيت المحلي (HKT) بالصينية، مع بث مباشر متزامن. سيلي ذلك بث مباشر باللغة الإنجليزية في الساعة 20:00 HKT/08:00 EDT.
HUTCHMED (NASDAQ/AIM/HKEX:HCM) 已宣布将于 2025年10月31日举办一次即将举行的研究与开发更新活动。演示将由 Dr. Michael Shi，执行副总裁、研发负责人兼首席医学官出席，他将讨论公司的研发策略与愿景。
此次活动将重点介绍 HUTCHMED 的 抗体靶向治疗偶联药物平台，并就其主导候选药物 HMPL-A251及后期阶段的管线进展进行更新。演示将于上海现场举行，时间为中国标准时15:00-17:00，使用中文，并提供同步网络直播。英文网络直播将于晚些时候在 20:00 HKT / 08:00 EDT 开启。
- None.
- None.
— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a Research & Development update in Shanghai, China, and via webcast on Friday, October 31, 2025.
During the event, Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED, will share insights into the Company’s R&D strategy and vision. This will include an overview of the Company’s Antibody Targeted Therapy Conjugates platform, featuring its lead candidate HMPL-A251, as well as updates on late-stage pipeline development.
The in-person event will be held in Shanghai from 3:00 p.m. to 5:00 p.m. HKT and conducted in Chinese (Putonghua). A live webcast will be available concurrently. Attendance at the in-person event is by invitation only.
A webcast in English will be held from 8:00 p.m. HKT / 8:00 a.m. EDT / 12:00 noon GMT on Friday, October 31, for approximately one hour.
Both webcasts will be available live via the company website at www.hutch-med.com/event/. A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
FAQ
When is HUTCHMED's R&D update presentation scheduled for 2025?
What topics will be covered in HUTCHMED's (HCM) October 2025 R&D presentation?
Who will be presenting at HUTCHMED's October 2025 R&D update?
How can investors access HUTCHMED's October 2025 R&D presentation?
